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Abstract
Background. In the Eurotransplant Senior Programme
(ESP), kidneys from donors aged ≥65 years are preferen-
tially allocated locally and transplanted into patients aged
≥65 years on dialysis. The purpose of this study was to
analyse whether the results of transplantation in the ESP
can be improved by preservation of organs by hypother-
mic machine perfusion (MP) compared with simple cold
storage (CS).
Methods. Overall, 85 deceased heart-beating donors ≥65
years of age were included in this analysis with follow-up
until 1 year post-transplant. For each donor, one kidney
was randomly assigned to preservation by CS and the
contralateral kidney to MP from organ procurement until
transplantation. Delayed graft function (DGF), primary
non-function (PNF) and 1-year patient and graft survival
rates were evaluated as primary and secondary endpoints.
Results. The median recipient age was 66 years in both
groups and the median cold ischaemia time was 11 h for
MP and 10.5 h for CS (P = 0.69). The DGF rate was
29.4% for MP and 34.1% for CS (P = 0.58). Only extended
duration of cold ischaemia time was an independent risk
factor for the development of DGF (odds ratio 1.2, P <
0.0001). PNF was signiﬁcantly reduced (3.5% MP versus
12.9% CS, P = 0.02). The 1-year patient and graft survival
rates were similar for MP and CS (94% versus 95% and 89
versus 81%, P > 0.05). The 1-year graft survival rate was
signiﬁcantly improved after MP in recipients who devel-
oped DGF (84% MP versus 48% CS, P = 0.01).
Conclusions. Continuous pulsatile hypothermic MP for
kidneys from donors aged ≥65 years can reduce the rate of
never-functioning kidneys and improve the 1-year graft
survival rate of kidneys with DGF. In this small cohort, the
known advantage of MP for the reduction of DGF could
not be conﬁrmed, possibly due to relatively short cold
ischaemia times.
Keywords: cold ischaemia time; delayed graft function; Eurotransplant
Senior Programme; graft survival; kidney transplantation
Introduction
Eurotransplant started the Eurotransplant Senior Pro-
gramme (ESP) in 1999. Kidneys from donors aged ≥65
years are matched with recipients aged ≥65 years [1].
Kidneys are allocated without Human Leukocyte Antigen
(HLA) matching in order to keep cold ischaemia times as
short as possible. If allocation to this group of recipients
is not possible, these kidneys are offered via the regular
Eurotransplant Kidney Allocation System to recipients
<65 years. If this also fails, the organs are ﬁnally offered
to centres that are free to choose one or two potential reci-
pients from their local waiting list [2].
The effectiveness of this allocation system has been
demonstrated on the basis of 5-year analysis of ESP data
by Frei et al. [3]. Cold ischaemia times and rates of
delayed graft function (DGF) were markedly reduced
compared with standard allocation based on HLA match-
ing. Five-year graft survival rates are similar or inferior to
those of standard criteria donor kidney transplantation in
this age group, but are considered acceptable as long-term
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results in the ESP are better than the expected results after
dialysis-only treatment [3–5].
The ﬁrst successful kidney transplant after 17 h of
machine perfusion (MP) was performed >40 years ago by
Belzer and Kountz [6]. Despite initial encouraging results,
MP was abandoned in favour of simple cold storage (CS),
mainly for logistical reasons when more effective CS
preservation solutions were introduced. However, the util-
ization of non-heart-beating and expanded criteria donor
(ECD) kidneys has resulted in a need for improved organ
preservation, leading to a renewed interest in MP.
A meta-analysis published in 2003 concluded that hy-
pothermic kidney MP reduced the risk of developing
DGF by up to 20% and the 10-year graft survival rate
could be increased by up to 6% [7]. Randomized studies
to clarify the exact inﬂuence of MP were not available at
that time. Our recently published randomized multicentre
study, which examined the effect of MP compared with
CS for all donors aged ≥16 years, showed an advantage
for MP, with less DGF in kidneys recovered from all
common types of deceased donors. In addition, we found
an improved 1-year graft survival rate, which was most
pronounced for ECD kidneys. [8–10]. So far, no data are
available for kidneys preserved by MP and transplanted in
the ESP setting. The objective of this study was to
analyse the effects of MP compared with CS for kidneys
from donors aged ≥65 years allocated in the ESP.
Materials and methods
Out of 132 potential deceased heart-beating donors, 85 donors with a
median age of 70 (65–83) years were included in this analysis
(Figure 1). In three donors (3.4%), the preservation method was switched
because of the vascular anatomy of the kidney assigned to MP. Initially,
Fig. 1. Trial proﬁle: enrolment, assignment and assessment of kidney pairs to MP or CS.
Kidney transplantation, machine perfusion, ESP, randomized controlled trial 4459
 by Laurent W
EEK






39 donors were included as part of the previously reported multicentre
randomized trial [8]. Prior to completion of patient enrolment of the
main study, it became evident that the number of ESP patients included
would not be sufﬁcient for a separate ESP subgroup analysis. Therefore,
the steering committee decided to continue enrolment of donors aged
≥65 years until at least 82 ESP donors had been included. This was
achieved for 85 donors by exactly following the main trial protocol in
the ensuing 9-month period.
All donors were heart-beating donors and were included in this study
only if both kidneys were transplanted into two different recipients.
Donors for combined organ transplantation were excluded. All organs
were allocated according to the ESP allocation system. At the time of
organ offer, recipient centres were blinded for the preservation method
(MP or CS) and pump parameters.
Trial logistics, randomization and preservation methods, as well as
the data collection method have been previously described in detail
[8, 9]. Brieﬂy, one kidney from each donor was randomized to MP and
the contralateral kidney to CS prior to the start of organ procurement.
After in situ ﬂush-out, kidneys assigned to MP were connected to a Life-
Port Kidney Transporter® (Organ Recovery Systems, Itasca, IL). A hy-
pothermic pulsatile ﬂow of Kidney Preservation Solution-1® (Organ
Recovery Systems) at a ﬁxed maximum systolic perfusion pressure of
30 mmHg was maintained during the entire cold ischaemia period.
Kidneys assigned to CS were submerged in preservation solution (either
University of Wisconsin solution or histidine–tryptophan–ketoglutarate)
and stored on melting ice.
The primary endpoint of this study was DGF, deﬁned as the need for
dialysis during the ﬁrst post-transplant week. The main secondary end-
points were functional DGF (f-DGF, deﬁned as the absence of a decrease
in serum creatinine level of at least 10% per day for at least 3 consecu-
tive days in the ﬁrst week after transplantation), primary non-function
(PNF), episodes of acute rejection and 1-year graft and patient survival
rates. Patients were treated post-transplant according to local standards
per recipient centre, which included induction and maintenance immuno-
suppression. As in the main study, the follow-up data were collected in a
secure online database hosted by Eurotransplant and were provided by
the 60 participating transplant centres.
The analysis was powered to detect a reduction in DGF of at least
20%, based on the assumption of a 40% incidence of DGF in recipients
with kidneys preserved by CS. With a power of 0.8 and a type I error of
0.05, the required sample size was at least 82 pairs of ECD kidneys. The
primary analysis of the DGF/PNF endpoint consisted of a logistic
regression model performed in an intention-to-treat and per-protocol
fashion with the covariates shown in Table 3. Differences between
groups were examined with Fisher’s exact test or the Mann–Whitney U-
test. Secondary endpoints were assessed using the Wilcoxon signed-rank
test or McNemar’s test. Variables that had a signiﬁcant inﬂuence on graft
failure were included in a Cox proportional hazards model. Graft and
patient survival rates were plotted in Kaplan–Meier curves and analysed
with the log-rank test. All calculations were performed with SPSS, SAS
and R software.
An independent scientiﬁc steering committee was responsible for all
aspects of this study. The study protocol was approved by the Eurotrans-
plant Ethical Advisory Committee and ethics committees in each trial
region. The study was sponsored by the Deutsche Forschungsge-
meinschaft (DFG TR 811/1-1) and by Organ Recovery Systems.
Results
Eighty-ﬁve donors resulting in 170 kidney transplants
allocated according to ESP guidelines were included in
this study. Donor and recipient details are summarized in
Table 1. For baseline characteristics, there were no differ-
ences between the two study groups. Re-transplantation
was performed in 23.5% of the recipients in the MP
group and 14.1% in the CS group (P = 0.30). The median
cold ischaemia times were similar in the two groups (MP
versus CS: 11 versus 10.5 h). None of the six kidneys
(three donors) where random assignment was switched,
because of technical reasons, developed DGF or PNF.
Primary endpoint
DGF occurred in 25 recipients (29.4%) in the MP group
and in 29 recipients (34.1%) in the CS group (P = 0.58;
Table 2). Logistic regression analysis also showed no
difference in DGF between the study groups. Only cold
ischaemia time [odds ratio (OR): 1.2, P < 0.0001) and
re-transplantation (OR: 3.99, P = 0.007) were signiﬁcantly
associated with the development of DGF (Table 3).
Analysis of DGF in an intention-to-treat model and
per-protocol fashion produces similar results (per-protocol
results not shown).
Secondary endpoints
There was a signiﬁcant difference in never-functioning
kidneys (PNF) between the two study groups. PNF
occurred in 3 recipients (3.5%) in the MP group and in
11 recipients (12.9%) in the CS group (P = 0.02). The
reasons for PNF in the MP group were vascular thrombo-
sis in one case and never achieving sufﬁcient function in
the absence of rejection/vascular thrombosis in two cases.
Table 1. Donor and recipient baseline characteristics
MP arm CS arm P-value
Donor
Age (years) 70 (65–83)
Gender (M/F) 40/45
BMI (kg/m2) 26 (21–40)










Age (years) 66 (39–79) 66 (37–79) 0.61
Gender (M/F) 55/30 59/26 0.31
Dialysis pre-Tx (years) 4.4 (0.5–9.1) 4.2 (1.14–8.0) 0.60
First/re-transplantation (n) 65/20 73/12 0.30
PRA pre-Tx ≤5% (n) 80 83 0.70
No HLA-A, -B, -DR mm (%) 1.2 1.2 0.93
Cold ischaemia time (hours) 11 (4–24) 10.5 (3–24) 0.69
Hospital stay (days) 21 (8–92) 23 (8–131) 0.19
MP, machine perfusion; CS, cold storage; Tx, transplantation; HTK,
histidine–tryptophan–ketoglutarate; UW, University of Winsconsin
solution; PRA, panel reactive antibodies; HLA mm, HLA mismatches.
Table 2. Results of univariate analysis
MP CS P-value
Delayed graft function (DGF; %) 29.4 34.1 0.58
Duration delayed graft function
(days)
12.5 (3–31) 13.0 (3–92) 0.33
f-DGF (%) 18.8 23.5 0.84
PNF (%) 3.5 12.9 0.02
CNI toxicity (%) 8.2 7.06 0.61
Acute rejection (%) 22.5 16.5 0.25
f-DGF, functional delayed graft function; PNF, primary non-function;
CNI, calcineurin inhibitor.
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In the CS group, PNF was caused by vascular thrombosis
in two cases, rejection in two cases never achieving sufﬁ-
cient function in the absence of rejection/vascular throm-
bosis in ﬁve cases and unknown in two cases. Serum
creatinine levels and creatinine clearance did not differ
between the two groups at any time point (data not
shown). There were also no differences in the duration of
DGF, in f-DGF or in the occurrence of calcineurin inhibi-
tor toxicity. 22.4% of recipients in the MP group and
16.5% in the CS group developed at least one episode of
acute rejection during the follow-up period (P = 0.25;
Table 2).
Patient and graft survival rates
One patient in the CS group and none in the MP group
died within the ﬁrst month after transplantation. Overall,
the 1-year patient survival rate was 95%. Within the ﬁrst
year after transplantation, ﬁve patients (5.8%) died in the
MP group and four patients (5%) in the CS group (P =
0.79). The 1-year graft survival rate was 89% in the MP
group and 81% in the CS group (P = 0.139; Figure 2).
When DGF occurred, the 1-year graft survival rate was
signiﬁcantly better after preservation with MP compared
with CS (84% versus 48%, P = 0.01; Figure 3). Among
the recipients with immediate graft function, 1-year graft
survival rates were 92% in the MP group and 98% in the
CS group (P = 0.109). In the Cox proportional hazards
model, only donor age signiﬁcantly inﬂuenced the graft
survival rate (OR: 1.12, P = 0.038; Table 4).
Discussion
The Eurotransplant Senior Programme (ESP) facilitates
timely kidney transplantation for elderly recipients while
effectively utilizing marginal donor organs [1]. Short- and
long-term results of ESP are acceptable, although inferior
compared with those of standard donors and recipients
[3, 4, 11]. One of the reasons for this is that aged ECD
kidneys are known to have decreased functional capacities
and are more susceptible to ischaemia-related damage
[12, 13]. Therefore, kidneys from elderly donors have the
potential to proﬁt most from improved preservation
methods.
In our recently reported randomized controlled trial,
MP reduced the risk of developing DGF in standard and
extended criteria donors, as well as in controlled non-
heart-beating donors [8–10]. The 1- and 3-year graft
survival rates were improved for MP kidneys from DBD
donors, but not for DCD kidneys [8, 9, 14]. To date, no
information about the effect of MP in programmes such
as the ESP had been available.
Fig. 3. The 1-year graft survival rate of kidney grafts with and without
DGF. MP, machine perfusion; CS, cold storage; DGF, delayed graft
function; the log-rank test of equality: MP versus CS in kidneys without
DGF, P = 0.11; MP versus CS in kidneys with DGF, P = 0.01; DGF
versus no DGF within CS group, P < 0.0001; DGF versus no DGF
within MP group, P = 0.27.
Table 4. The Cox proportional hazards model—dependent variable graft
failure within 1 year after transplantation (intention-to-treat analysis)
Hazard ratio (95% CI) P-value
MP versus CS 0.48 (0.21–1.11) 0.887
Recipient age 1.02 (0.93–1.13) 0.610
Donor age 1.12 (1.01–1.24) 0.038
CI, conﬁdence interval; MP, machine perfusion; CS, cold storage.
Fig. 2. The 1-year graft survival rate. MP, machine perfusion; CS, cold
storage; the log-rank test of equality: MP versus CS, P = 0.14.
Table 3. The logistic regression model—dependent variable delayed
graft function (intention-to-treat analysis)
Odds ratio (95% CI) P-value
MP versus CS 0.68 (0.32–1.43) 0.315
CIT 1.20 (1.10–1.31) <0.0001
HLA mm 1.33 (0.98–1.83) 0.072
PRA 1.03 (0.99–1.07) 0.184
Recipient age 1.04 (0.98–1.12) 0.204
Donor age 1.06 (0.98–1.15) 0.125
First versus re-transplantation 3.99 (1.49–11.13) 0.007
Length of dialysis 1.22 (0.98–1.52) 0.076
CI, conﬁdence interval; MP, machine perfusion; CS, cold storage; CIT,
cold ischaemia time; HLA mm, HLA mismatches; PRA, panel reactive
antibodies
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The overall results of the present study concur with the
ESP data published so far. However, the DGF rate of
34.1% in the CS arm was somewhat higher than the pre-
viously reported rates [3, 15, 16]. On the other hand, the
DGF rate in the CS arm was also lower than the originally
estimated 40% that had been used to calculate the re-
quired sample size for this study. The exclusion of poten-
tially high-risk kidneys derived from donors of whom
only one kidney had been accepted for transplantation
may have led to an under-estimation of DGF rates in both
the arms of our study. Compared with the overall study,
this potential bias by exclusion of high-risk donor kidneys
was less counterbalanced by exclusion of low-risk donor
kidneys that were transplanted together with another
organ into the same recipient, as these procedures are not
part of the ESP programme.
In retrospective analyses, Matsuoka and Stratta showed
that MP can signiﬁcantly reduce DGF in ECD kidneys
compared with cold storage. PNF was not reduced in
these studies, but the overall rate of PNF after MP in our
study was comparable [17, 18].
In the present study, MP reduced DGF by 4.7% from
34.1 to 29.4%. This difference was not statistically signiﬁ-
cant in univariate or multivariate analysis. This may be
due to the relatively small number of patients included in
this study, but it may also be explained by the relatively
short median cold ischaemia time. Due to the method of
allocation in ESP, the median cold ischaemia time in this
study (10.8 h) was much lower than that in the retrospec-
tive analyses of Matsuoko and Stratta (19–24.5 h) [17, 18].
It was also lower than in the overall study (15 h) [8], still
lower than in the analysis focusing on ECD results (13 h)
[9]) and even lower than in the ESP report by Frei et al.
(11.9 h) [3].
Our data contrast with previously published data by
Schold et al. [19], who did demonstrate a signiﬁcant
effect of MP on the incidence of DGF, even with median
cold ischaemia times under 12 h. Re-transplantation was a
strong and signiﬁcant risk factor for the development of
DGF compared with primary transplantation. The re-
transplantation rate was higher in the MP group than that
in the CS group. Although this difference was not signiﬁ-
cant, it could still have exerted a relevant negative inﬂu-
ence on the DGF rate in the MP group. The high rate of
exclusions may also partially explain why the anticipated
DGF risk reduction of 20% could not be shown. Our
study ﬁnally demonstrated a relative risk of 0.68.
The rate of never-functioning grafts (PNF) of almost 13%
in the CS group in this study was much higher than the
7.3% reported earlier by Frei et al. [3], even though the
median cold ischaemic time of 10.5 h was much lower. This
indicates the urgent need for viability testing and improved
preservation methods in these high-risk donor organs.
One of the most interesting and clinically relevant ﬁnd-
ings of this study is that the rate of PNF was signiﬁcantly
lower in the MP group than that in the CS group. While
the PNF rate of 3.5% in the MP arm is comparable to
rates reported for well-selected ECD kidneys [17, 18], the
12.9% PNF rate in the CS arm exceeds PNF rates pre-
viously reported for the ESP in 1999–2004 by 5.6% [3].
Compared with UNOS registry data and single-centre
retrospective analysis of PNF rates of kidneys from older
donors in North America, the PNF rates in the CS arm of
our study are much higher than expected, even though
reported cold ischaemia times were usually much longer
[17, 18]. The most likely explanations for this discrepancy
are the high discard rate of up to 50% of kidneys from
donors ≥65 years of age in the UNOS region [20], the
use of MP for preservation in some cases [21, 22] and the
routine use of histopathology analysis for selecting
kidneys, which is usually not available within the Euro-
transplant region [20, 23].
The overall frequency of acute rejection in this study
was not signiﬁcantly different in the MP versus the CS
arm and similar to the donor and recipient age-corrected
UNOS data [24]. HLA matching has the potential to
reduce acute rejection [25, 26]. Possibly due to the re-
cently recognized more severe immune response in grafts
from older donors, acute rejection rates in the ESP are
much higher than previously anticipated. The rationale for
the ESP was that local allocation and short CIT are more
important than HLA matching. Based on our ﬁndings,
one could argue that a component of HLA matching
should be included in the allocation algorithm, when
these very old kidneys are preserved by MP, even if this
would lead to a slightly longer CIT.
The mechanisms of the clinically relevant beneﬁt of
MP remain unclear. In theory, the elimination of toxins,
protective endothelial gene expression during pulsatile
perfusion, decrease of vasospasm and several other mech-
anisms are discussed but not yet fully understood [27].
Nevertheless, the application of MP in kidneys from
donors ≥65 years of age could be a valuable tool to
safely decrease the discard rate of those marginal kidneys.
The 1-year patient survival rate of nearly 95% in ESP
kidney recipients was similar to that in the overall study
(97%) with much younger donors and recipients. ESP
results published so far have reported patient survival
rates ranging between 80 and 95%, conﬁrming that
higher recipient age is not a contraindication per se
[3, 15, 28, 29].
While a signiﬁcant advantage in the graft survival rate
up to 1-year post-transplant could be shown in the overall
study (94 MP versus 90% CS, P = 0.04) [8], the analysis
of this smaller series of patients could not demonstrate a
similar advantage. There was, however, a statistically
signiﬁcant and highly clinically relevant difference in the
graft survival rate if DGF occurred.
One possible shortcoming of this analysis is that the
design of the overall study did not anticipate subgroup
analysis and that the ECD and ESP donor population are
partly overlapping. Furthermore, even though an
additional 46 donors ≥65 years were enrolled, the overall
number of included patients only allows for detection of
larger differences. However, we feel that this study under-
lines the importance of very short cold ischaemia times
for kidneys recovered from very old donors. Although we
could not show a signiﬁcant effect of MP on DGF, the
reduced rate of PNF, as well as the improved graft survival
rate of kidneys that developed DGF indicates that MP is a
valuable tool for addressing the forthcoming challenges in
kidney transplantation from donors of advanced age.
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